Assay Detail
Binding
CHEMBL1663322
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of CK2 assessed as inhibition of [gamma32P]GTP incorporation into substrate by liquid scintillation counting
2
Total Activities
2
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Confidence | 0 — Uncurated / Unknown |
| Curated By | Autocuration |
Publication
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 2 | 5.26 | 5.70 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL289277 | EMODIN | — | 1 | 5.70 |
| CHEMBL375530 | DICHLORORIBOBENZIMIDAZOLE | — | 1 | 4.82 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL289277 | EMODIN | IC50 | = | 2000.0 | nM | 5.70 |
| CHEMBL375530 | DICHLORORIBOBENZIMIDAZOLE | IC50 | = | 15000.0 | nM | 4.82 |